/Investor DB

Biotechnology Value Fund — 2020 Investments

3 investments dated 2020 · listed companies and verified rows first · show all

4D Molecular Therapeutics4dmoleculartherapeutics.cominNASDAQ: FDMTJun 2020 · $75M

4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.

BiotechHealthtechEmeryville, US

David Kirn(Chief Executive Officer, President, and Co-Founder)inDavid Schaffer(Director)inTheresa Janke(Chief of Staff, Co-Founder)in

BoardSharon Tetlow(Director)Margi McLoughlin(Director)

Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityCasdin CapitalChiesi VenturesHercules Capital, Inc.+8 more

Dren Biodrenbio.comOct 2020 · $60M

Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.

BiotechHealthtechMedical DevicesFoster City, US

Nenad Tomasevic(Founder)

BoardIvan Trifunovich(Director)John Wesley(Founder)

Co-investors8VCAisling CapitalHBM Healthcare InvestmentsHBM PartnersJacket River Capital PartnersMission Bay Capital+5 more

Rain TherapeuticsinSep 2020 · $63M

BiotechFremont, US

Avanish Vellanki(Executive Officer)in

Co-investorsJanus Henderson InvestorsSamsara BioCapital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.